EICHORCondition: Various Advanced Cancer · Sponsor: Bristol-Myers Squibb
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Alaska Urological Institute dba Alaska Clinical Research Center | Anchorage, Alaska, United States | — |
| Local Institution - 0179 | Tucson, Arizona, United States | — |
| Local Institution - 0061 | Clovis, California, United States | — |
| Local Institution - 0172 | Sacramento, California, United States | — |
| Local Institution - 0005 | San Francisco, California, United States | — |
| Local Institution - 0178 | Lakewood, Colorado, United States | — |
| Local Institution - 0167 | Gainesville, Florida, United States | — |
| Local Institution - 0030 | Miami Beach, Florida, United States | — |
| Local Institution - 0008 | Tampa, Florida, United States | — |
| Local Institution - 0168 | Maywood, Illinois, United States | — |
| Local Institution - 0094 | Fort Wayne, Indiana, United States | — |
| Local Institution - 0171 | New Orleans, Louisiana, United States | — |
+ 176 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02632409